Drugs / PoliorixTM
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01323647 | Apr → Sep 2011 | poliomyelitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00920439 | Jun → Aug 2009 | poliomyelitis | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PoliorixTM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00920439 ↗ |
| Known as | Poliorix | “non-inferiority of IPV (Poliorix™, GSK Vaccines, Belgium) versus OPV” PMID 26873055 ↗ Feb 2016 |
| Modality | Vaccine | “inactivated poliovirus vaccine (IPV)” PMID 26873055 ↗ Feb 2016 |
| Route | Intramuscular | “by intramuscular injection (IM).” NCT00920439 ↗ |